Publications by authors named "Joseph P Boni"

Claim this Profile
Q
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy.
Yuezhe Li, A Katharina Wilkins, Jimena Davis, Timothy Knab, Marie Toukam, Joseph P Boni

NPJ Syst Biol Appl· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Marie Toukam, Joseph P Boni, Mehdi Hamadani, Paolo F Caimi, Hans G Cruz

Cancer Chemother Pharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
Marie Toukam, Jens Wuerthner, Karin Havenith, Mehdi Hamadani, Paolo F Caimi, Joseph P Boni

Cancer Chemother Pharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.
Jennifer E Hibma, Hagop M Kantarjian, Daniel J DeAngelo, Joseph P Boni

Br J Clin Pharmacol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Romano Danesi, Joseph P Boni, Alain Ravaud

Cancer Treat Rev· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.
Joseph P Boni, Cathie Leister, Bruce Hug, Jaime Burns, Daryl Sonnichsen

Cancer Chemother Pharmacol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Birgit Geoerger, Mark W Kieran, Stephan Grupp, Danuta Perek, Jill Clancy, Joseph P Boni

Eur J Cancer· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Sheri L Spunt, Stephan A Grupp, Terry A Vik, Victor M Santana, David J Greenblatt, Joseph P Boni

J Clin Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
Jan C Buckner, Bahram Forouzesh, Charles Erlichman, Manuel Hidalgo, Joseph P Boni

Invest New Drugs· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
Joseph P Boni, Bruce Hug, Cathie Leister, Daryl Sonnichsen

Semin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Robert J Motzer, Gary R Hudes, Brendan D Curti, David F McDermott, Bernard J Escudier, Joseph P Boni

J Clin Oncol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Manuel Hidalgo, Jan C Buckner, Charles Erlichman, Marilyn S Pollack, Joseph P Boni

Clin Cancer Res· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Charles Erlichman, Manuel Hidalgo, Joseph P Boni, Patricia Martins, Susan E Quinn

J Clin Oncol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.
Joseph P Boni, Cathie Leister, Gregor Bender, Virginia Fitzpatrick, Natalie Twine

Clin Pharmacol Ther· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Michael B Atkins, Manuel Hidalgo, Walter M Stadler, Theodore F Logan, Janice P Dutcher, Joseph P Boni

J Clin Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis